PriceTargets.com logo

NASDAQ:TRDA - Entrada Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 59.49 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.27 As of 05/25/2022 05:00 PM ET
▲ +0.27 (4.50%)

This chart shows the closing price for TRDA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Entrada Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRDA

Analyst Price Target is $10.00
▲ +59.49% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Entrada Therapeutics in the last 3 months. The average price target is $10.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 59.49% upside from the last price of $6.27.

This chart shows the closing price for TRDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Entrada Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2022The Goldman Sachs GroupLower Price TargetNeutral$22.00 ➝ $10.00High
11/24/2021Evercore ISIInitiated CoverageOutperformHigh
11/23/2021CowenInitiated CoverageOutperformHigh
11/23/2021The Goldman Sachs GroupInitiated CoverageNeutral$29.00High
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/26/2022

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Entrada Therapeutics logo
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $6.27
Low: $5.91
High: $6.50

50 Day Range

MA: $7.46
Low: $5.49
High: $11.15

52 Week Range

Now: $6.27
Low: $5.12
High: $36.85

Volume

62,574 shs

Average Volume

93,172 shs

Market Capitalization

$196.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Entrada Therapeutics?

The following Wall Street analysts have issued research reports on Entrada Therapeutics in the last twelve months: Cowen Inc, Evercore ISI, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for TRDA.

What is the current price target for Entrada Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Entrada Therapeutics in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 66.7%.
View the latest price targets for TRDA.

What is the current consensus analyst rating for Entrada Therapeutics?

Entrada Therapeutics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TRDA will outperform the market and that investors should add to their positions of Entrada Therapeutics.
View the latest ratings for TRDA.

How do I contact Entrada Therapeutics' investor relations team?

The company's listed phone number is 857-520-9158 and its investor relations email address is [email protected] The official website for Entrada Therapeutics is www.entradatx.com. Learn More about contacing Entrada Therapeutics investor relations.